AbbVie 2012 Annual Report Download - page 139

Effective February 17, 2012, he received long-term incentives, including a 19,600 share stock option
grant and a 10,900 share performance-vesting restricted stock award. Effective December 1, 2012,
related to his appointment as Executive Vice President, Chief Financial Officer of AbbVie, Mr. Chase’s
base salary was set at $790,000 and his bonus target for 2013 was set at 105 percent of base salary;
additionally, he received a 23,066 share performance-vesting restricted stock award. The award
converted 100 percent to AbbVie performance-vesting restricted stock at Separation. The award will
cliff vest after January 1, 2016, subject to continued employment with AbbVie and the satisfaction of
AbbVie performance criteria. Mr. Chase’s bonus for 2012 was based on his salary and bonus target in
effect at the beginning of 2012.
Carlos Alban
Effective February 15, 2013, Mr. Alban was awarded a bonus of $675,000, which was above his
target bonus of 100 percent of base pay. Effective January 31, 2013, he received a discretionary cash
bonus of $300,000 in recognition of performance related to the business separation, which was earned
and accrued for in 2012. Effective February 17, 2012, he received long-term incentives, including a
48,100 share stock option grant and a 26,700 share performance-vesting restricted stock award.
Effective December 1, 2012, related to his appointment as Executive Vice President, Commercial
Operations of AbbVie, Mr. Alban’s base salary was set at $710,000 and his bonus target for 2013 was
set at 105 percent of base salary. He also received an 18,453 share performance-vesting restricted stock
award, which converted 100 percent to AbbVie performance-vesting restricted stock at Separation. The
award will cliff vest after January 1, 2016, subject to continued employment with AbbVie and the
satisfaction of AbbVie performance criteria. Mr. Alban’s bonus for 2012 was based on his salary and
bonus target in effect at the beginning of 2012.
John M. Leonard, M.D.
Effective February 15, 2013, Mr. Leonard was awarded a bonus of $515,600, which was below his
target bonus of 90 percent of base pay. Effective February 17, 2012, he received long-term incentives,
including a 33,000 share stock option grant and an 18,300 share performance-vesting restricted stock
award. Effective December 1, 2012, related to his appointment as Senior Vice President, Chief
Scientific Officer of AbbVie, Mr. Leonard’s base salary was set at $700,000 and his bonus target for
2013 was set at 100 percent of base salary. He also received an 18,453 share performance-vesting
restricted stock award, which converted 100 percent to AbbVie performance-vesting restricted stock at
Separation. The award will cliff vest after January 1, 2016, subject to continued employment with
AbbVie and the satisfaction of AbbVie performance criteria. Mr. Leonard’s bonus for 2012 was based
on his salary and bonus target in effect at the beginning of 2012.
Post Termination and Other Benefits
Each of the benefits described below supports the Company’s objective of providing a market
competitive total rewards program. Individual benefits do not directly affect decisions regarding other
benefits or pay components, except to the extent that all benefits and pay components must, in the
aggregate, be competitive, as previously discussed. Mr. Gonzalez, who had retired from Abbott in 2007,
returned to work at Abbott in 2009. Upon his return to Abbott, Mr. Gonzalez did not become an
active participant in any of Abbott’s employee benefits plans. Instead, he continued to receive
previously earned Abbott retiree benefits, including pension and retiree healthcare benefits through
December 31, 2012. As of January 1, 2013, Mr. Gonzalez discontinued receiving retiree benefits and
began participating in AbbVie’s employee benefit plans for active employees. As of January 1, 2013,
AbbVie assumed responsibility for providing post-termination and other benefits for its named
executive officers.
25